Home > Boards > US Listed > Biotechs > MultiCell Technologies (MCET)

Latest Information Update: 28 Sep 2018: Research programme:

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
TPX Member Profile
Member Level 
Followed By 540
Posts 35,776
Boards Moderated 6
Alias Born 10/24/13
160x600 placeholder
TPX Member Level  Monday, 10/08/18 01:09:02 PM
Re: None
Post # of 43268 
Latest Information Update: 28 Sep 2018: Research programme: anticancer and antiviral therapeutics - MultiCell Technologies

Alternative Names: Ig-NP; IgP therapeutic; MCT-475; MCT-485
Latest Information Update: 28 Sep 2018

At a glance
Originator MultiCell Technologies Inc
Developer MultiCell Technologies Inc; University Health Network
Class Immunoglobulin fusion proteins; Recombinant fusion proteins; RNA
Mechanism of Action Apoptosis stimulants; Immunomodulators; Immunostimulants; T lymphocyte stimulants; Toll-like receptor 3 agonists; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists; Toll-like receptor agonists; Tumour necrosis factor alpha stimulants
Orphan Drug Status No
New Molecular Entity Yes
Highest Development Phases
No development reported Cancer; Liver cancer; Viral hepatitis
Most Recent Events
28 Sep 2018 No recent reports of development identified for preclinical development in Viral-hepatitis in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
04 Nov 2017 No recent reports of development identified for preclinical development in Liver cancer in USA (Parenteral)

https://adisinsight.springer.com/drugs/800025804

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist